18.24
price up icon7.29%   1.24
after-market Handel nachbörslich: 18.23 -0.010 -0.05%
loading
Schlusskurs vom Vortag:
$17.00
Offen:
$16.78
24-Stunden-Volumen:
3.28M
Relative Volume:
1.63
Marktkapitalisierung:
$1.70B
Einnahmen:
$352.57M
Nettoeinkommen (Verlust:
$-143.01M
KGV:
-10.08
EPS:
-1.81
Netto-Cashflow:
$-153.40M
1W Leistung:
+7.29%
1M Leistung:
-21.72%
6M Leistung:
-21.21%
1J Leistung:
-23.68%
1-Tages-Spanne:
Value
$16.66
$19.48
1-Wochen-Bereich:
Value
$16.04
$19.48
52-Wochen-Spanne:
Value
$13.53
$35.25

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name
Firmenname
Beam Therapeutics Inc
Name
Telefon
857-327-8775
Name
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Mitarbeiter
483
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
BEAM's Discussions on Twitter

Vergleichen Sie BEAM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BEAM
Beam Therapeutics Inc
18.24 1.70B 352.57M -143.01M -153.40M -1.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-28 Hochstufung BofA Securities Neutral → Buy
2025-03-10 Hochstufung Scotiabank Sector Perform → Sector Outperform
2025-01-29 Hochstufung Cantor Fitzgerald Neutral → Overweight
2024-11-06 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-07-23 Eingeleitet H.C. Wainwright Buy
2024-01-29 Hochstufung JP Morgan Neutral → Overweight
2023-12-15 Herabstufung BofA Securities Buy → Neutral
2023-12-08 Herabstufung Jefferies Buy → Hold
2023-10-20 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-10-20 Herabstufung Leerink Partners Outperform → Market Perform
2023-03-21 Eingeleitet Bernstein Mkt Perform
2023-02-01 Eingeleitet Cantor Fitzgerald Overweight
2022-12-20 Hochstufung BMO Capital Markets Market Perform → Outperform
2022-12-13 Eingeleitet Citigroup Buy
2022-06-17 Eingeleitet BMO Capital Markets Market Perform
2022-04-28 Eingeleitet Credit Suisse Neutral
2022-01-05 Eingeleitet Guggenheim Buy
2021-10-19 Eingeleitet SVB Leerink Outperform
2021-09-24 Fortgesetzt Stifel Buy
2021-09-10 Eingeleitet BofA Securities Buy
2021-05-11 Eingeleitet Redburn Buy
2021-05-04 Eingeleitet RBC Capital Mkts Sector Perform
2021-03-01 Herabstufung Barclays Overweight → Equal Weight
2021-02-16 Eingeleitet Wells Fargo Overweight
2021-01-29 Herabstufung JP Morgan Overweight → Neutral
2021-01-06 Eingeleitet Stifel Hold
2020-08-05 Eingeleitet William Blair Outperform
2020-03-02 Eingeleitet Barclays Overweight
2020-03-02 Eingeleitet JP Morgan Overweight
2020-03-02 Eingeleitet Jefferies Buy
2020-03-02 Eingeleitet Wedbush Outperform
Alle ansehen

Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten

pulisher
10:36 AM

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga

10:36 AM
pulisher
Apr 20, 2025

Recent uptick might appease Beam Therapeutics Inc. (NASDAQ:BEAM) institutional owners after losing 29% over the past year - simplywall.st

Apr 20, 2025
pulisher
Apr 14, 2025

How To Trade (BEAM) - news.stocktradersdaily.com

Apr 14, 2025
pulisher
Apr 12, 2025

Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? - MSN

Apr 12, 2025
pulisher
Apr 11, 2025

Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance

Apr 11, 2025
pulisher
Apr 10, 2025

Cathie Wood's ARK ETF focuses on Beam Therapeutics, Coinbase stock - Investing.com

Apr 10, 2025
pulisher
Apr 08, 2025

Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal - streetwisereports.com

Apr 08, 2025
pulisher
Apr 08, 2025

Share Price Appreciation of Biotech Due Over Next Six Months - streetwisereports.com

Apr 08, 2025
pulisher
Apr 07, 2025

H.C. Wainwright maintains $80 target on Beam Therapeutics stock By Investing.com - Investing.com India

Apr 07, 2025
pulisher
Apr 07, 2025

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease - AOL.com

Apr 07, 2025
pulisher
Apr 07, 2025

H.C. Wainwright maintains $80 target on Beam Therapeutics stock - Investing.com

Apr 07, 2025
pulisher
Apr 06, 2025

Beam Therapeutics Presents Additional Data for BEAM-302 in - GlobeNewswire

Apr 06, 2025
pulisher
Apr 05, 2025

Beam Presents Addl. Data From Phase 1/2 Trial Of BEAM-302 In Alpha-1 Antitrypsin Deficiency - Nasdaq

Apr 05, 2025
pulisher
Apr 05, 2025

Breakthrough: New BEAM-302 Data Shows 91% Success Rate in Rare Liver Disease Treatment - Stock Titan

Apr 05, 2025
pulisher
Apr 04, 2025

Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed' - Benzinga

Apr 04, 2025
pulisher
Apr 04, 2025

Beam Therapeutics executive sells $55,330 in stock By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

Beam Therapeutics executive sells $55,330 in stock - Investing.com Australia

Apr 04, 2025
pulisher
Apr 03, 2025

Beam Therapeutics’ chief legal officer sells $104,121 in stock By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 03, 2025

Beam Therapeutics’ chief legal officer sells $104,121 in stock - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Beam Therapeutics CEO John Evans sells $562,684 in stock By Investing.com - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Beam Therapeutics CEO John Evans sells $562,684 in stock - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Beam Therapeutics president sells $136,418 in stock - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Beam Therapeutics Executives Sell Shares for Tax Obligations and Personal Sales - TradingView

Apr 03, 2025
pulisher
Apr 03, 2025

7 Top Gene-Editing Stocks to Buy | Investing | U.S. News - Money/ US News

Apr 03, 2025
pulisher
Apr 02, 2025

Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io

Apr 02, 2025
pulisher
Apr 01, 2025

Beam Therapeutics Becomes Oversold - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

8 Best Gene-Editing Stocks to Buy - Insider Monkey

Mar 31, 2025
pulisher
Mar 31, 2025

Biotech stocks plunge as FDA’s Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance

Mar 31, 2025
pulisher
Mar 31, 2025

BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance - MSN

Mar 31, 2025
pulisher
Mar 29, 2025

Beam Therapeutics (BEAM) Upgraded to Buy by Bank of America on P - GuruFocus

Mar 29, 2025
pulisher
Mar 28, 2025

Beam Therapeutics (BEAM) Upgraded by BofA on Promising Genetic T - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

B of A Securities Upgrades Beam Therapeutics (BEAM) - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Beam upgraded to Buy at BofA Securities on recent genetic condition treatment - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

B of A Securities Upgrades Beam Therapeutics (BMV:BEAM) - Nasdaq

Mar 28, 2025
pulisher
Mar 28, 2025

Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

BofA raises Beam Therapeutics stock rating to Buy, sets $42 target - Investing.com Canada

Mar 28, 2025
pulisher
Mar 28, 2025

BofA raises Beam Therapeutics stock rating to Buy, sets $42 target By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

BofA Securities Upgrades Beam Therapeutics to Buy From Neutral - Marketscreener.com

Mar 28, 2025
pulisher
Mar 27, 2025

FDA Clears Beam Therapeutics' (BEAM) Drug for Genetic Disease Tr - GuruFocus

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics gets trial authorization for its genetic disorder treatment in U.S. - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics New Drug Application for Alpha-1 Antitrypsin Deficiency Gets FDA Clearance - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial - Investing.com India

Mar 27, 2025

Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):